Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) will present results of its Phase 1b study of PTX-100 in T-cell lymphomas during a poster presentation at the 5th World Congress of Cutaneous Lymphomas (WCCL) to be held in Pasadena, California, from April 11-13, 2024.
Cutaneous TCLs (CTCLs) represent roughly one-third of T-cell lymphomas (TCLs). With a prevalence of around 30,000 cases, it is considered an orphan disease with a need for more effective therapies, especially in relapsed and refractory patients.
Held every four years, the WCCL is a specialist forum to discuss the latest advances in the field of cutaneous lymphomas. It is attended by global key opinion leaders and multi-discipline participants in this specialist field.
Professor H. Miles Prince, AM, a renowned lymphoma expert and Principal Investigator of the PTX-100 study, will present the poster, which focuses on PTX-100 data in relapsed and refractory cutaneous CTCL.
Prescient’s Phase 1b trial of PTX-100 in TCLs has concluded enrolment, although two patients remain on study. Since the last update, an additional patient with CTCL — the last patient enrolled to the study — has experienced a clinical response (partial response).
"Significant advancements in the field"
Prescient Therapeutics managing director and CEO Steven Yatomi-Clarke said, “It is a privilege to have our abstract presented at 5th WCCL, especially as the congress is only held every four years, and seeks to highlight significant advancements in the field during this time.
“It is also timely to meet with key opinion leaders in the field ahead of our planned Phase 2 study this year. Whilst CTCL is a subset of all TCLs, it is still an area of poorly met clinical need, especially in the relapsed and refractory setting.
“This latest clinical response adds to the encouraging data we have previously observed in this study which includes an overall response rate of 45%. It is pleasing that our therapy continues to exhibit clinical activity and favourable safety in this patient population.”